摘要
目的评价吉非替尼二线和三线方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法选择符合入组条件的38例晚期NSCLC,均给予吉非替尼250 mg/d,口服,1个月为1个治疗周期,每个周期结束后进行疗效评价。有效者继续治疗,直至出现疾病进展或发生不可耐受的药物毒副反应。结果38例均可评价疗效,总有效率(RR)为31.6%(12/38),临床受益率(CBR)为86.8%(33/38),中位疾病进展时间为5.8个月,1年生存率为42.1%(16/38),腺癌患者的有效率明显高于鳞癌患者(P<0.05)。15例(39.5%)至少出现一种药物相关性毒副反应,但多数较轻,且可逆。主要毒副反应为皮疹。结论吉非替尼二线和三线方案治疗晚期NSCLC有较好疗效,且毒副反应可耐受。
Objective To evaluate the efficacy and toxicity of gefitinib as second-line or even third-line regimen in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods 38 patients with advanced NSCLC were eligible for this study were selected,and were given treatment.The regimen was oral instake of gefitinib 250 mg once daily,1 month was 1 cycle,and the efficacy and toxicity were evaluated after 1 cycle,the effective patients were given treatment continuously until the disease progression were observed or the toxicity had become intolerable.Results 38 patients were evaluable for the efficacy and toxicity.The overall response rate and the clinical benefit rate were 31.6%（12/38） and 86.8%（33/38）,respectively.The median time to progression was 5.8 months.The 1-year survival rate was 42.1%（16/38）.The response rate in adenocarcinoma patients was higher than that in squamous cell carcinoma patients（P〈0.05）.At least one kind of toxicity would be observed in 15 patients（39.5%）,however,it was mild and reversible.The main toxicity was skin rash.Conclusion Gefitinib is effective as a second-line or even third-line regimen in the treatment of patients with advanced non-small cell lung cancer,and the toxicity is intolerable.
出处
《肿瘤基础与临床》
2010年第1期21-23,共3页
journal of basic and clinical oncology
关键词
晚期非小细胞肺癌
吉非替尼
靶向治疗
advanced non-small cell lung cancer
gefitinib
targeted therapy
